sulfinpyrazone has been researched along with Hyperlipemia in 11 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preliminary data obtained in the ambit of Anturan Reinfarction Italian Study (ARIS) show that, in postmyocardial infarction, reduced platelet survival time occurred in hyperbetalipoproteinemic patients treated with placebo, but not in the group of patients treated with sulfinpyrazone (interaction between treatment and lipemic level is at p approximately equal to 0." | 9.04 | A controlled study of the effect of sulfinpyrazone on platelet survival and on platelet-bound 14C-serotonin release in patients with previous myocardial infarction. ( Basagni, M; Boschetti, C; Cortellaro, M; Fassio, G; Polli, EE, 1979) |
| "Preliminary data obtained in the ambit of Anturan Reinfarction Italian Study (ARIS) show that, in postmyocardial infarction, reduced platelet survival time occurred in hyperbetalipoproteinemic patients treated with placebo, but not in the group of patients treated with sulfinpyrazone (interaction between treatment and lipemic level is at p approximately equal to 0." | 5.04 | A controlled study of the effect of sulfinpyrazone on platelet survival and on platelet-bound 14C-serotonin release in patients with previous myocardial infarction. ( Basagni, M; Boschetti, C; Cortellaro, M; Fassio, G; Polli, EE, 1979) |
| "Gout is increasingly recognized as the most common form of inflammatory arthritis worldwide; however, no Canadian data on the disease burden of gout are available." | 1.46 | The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012. ( Aviña-Zubieta, JA; Choi, HK; De Vera, MA; McCormick, N; Rai, SK; Sayre, EC; Shojania, K, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (90.91) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rai, SK | 1 |
| Aviña-Zubieta, JA | 1 |
| McCormick, N | 1 |
| De Vera, MA | 1 |
| Shojania, K | 1 |
| Sayre, EC | 1 |
| Choi, HK | 1 |
| Greco, R | 1 |
| Siciliano, S | 1 |
| Gentile, F | 1 |
| Elia, L | 1 |
| Murena, E | 1 |
| Forni, N | 1 |
| Boccalatte, A | 1 |
| Marsico, F | 1 |
| Paredero Del Bosque Martin, V | 1 |
| Cortellaro, M | 1 |
| Boschetti, C | 1 |
| Fassio, G | 1 |
| Basagni, M | 1 |
| Polli, EE | 1 |
| Mustard, JF | 1 |
| Packham, MA | 1 |
| Kinlough-Rathbone, RL | 1 |
| Strano, A | 1 |
| Novo, S | 1 |
| Latour, JG | 1 |
| Groulx, C | 1 |
| Léger-Gauthier, C | 1 |
| Nenci, GG | 1 |
| Agnelli, G | 1 |
| Berrettini, M | 1 |
| Parise, P | 1 |
| Ballatori, E | 1 |
| Steele, P | 1 |
| Battock, D | 1 |
| Genton, E | 1 |
| Renaud, S | 1 |
| Lecompte, F | 1 |
| Holländer, E | 1 |
| Schwarczmann, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311] | Phase 4 | 70 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337] | Phase 4 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| Arm 1 of 5 Randomized Treatment Arms | 27.6 |
| Arm 2 of 5 Randomized Treatment Arms | 27.0 |
| Arm 3 of 5 Randomized Treatment Arms | 31.4 |
| Arm 4 of 5 Randomized Treatment Arms | 25.7 |
| Arm 5 of 5 Randomized Treatment Arms | 28.3 |
Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| 1 of 5 Randomized Treatment Arms | 10.0 |
| 2 of 5 Randomized Treatment Arms | 11.2 |
| 3 of 5 Randomized Treatment Arms | 10.0 |
| 4 of 5 Randomized Treatment Arms | 11.0 |
| 5 of 5 Randomized Treatment Arms | 9.6 |
2 reviews available for sulfinpyrazone and Hyperlipemia
| Article | Year |
|---|---|
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
[Prospects of antiaggregant therapy in prevention of atherosclerosis].
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Arteriosclerosis; Aspirin; Blood Coagulation Diso | 1979 |
1 trial available for sulfinpyrazone and Hyperlipemia
| Article | Year |
|---|---|
A controlled study of the effect of sulfinpyrazone on platelet survival and on platelet-bound 14C-serotonin release in patients with previous myocardial infarction.
Topics: Adult; Aged; Blood Platelets; Cell Survival; Cholesterol; Clinical Trials as Topic; Female; Humans; | 1979 |
8 other studies available for sulfinpyrazone and Hyperlipemia
| Article | Year |
|---|---|
The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012.
Topics: Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; British Columbia; Colchicine; Comorbidit | 2017 |
[Prevention of ischemic cardiopathy, with special reference to secondary prevention in the post-infarct period].
Topics: Adrenergic beta-Antagonists; Coronary Artery Bypass; Heart Failure; Humans; Hyperlipidemias; Hyperte | 1981 |
[Indications for surgical treatment and medical treatment of atherosclerosis].
Topics: Arteriosclerosis; Aspirin; Cholestyramine Resin; Clofibrate; Dextrothyroxine; Dipyridamole; Humans; | 1980 |
Activation of the Hageman factor-prekallikrein system in the pathogenesis of the generalized Shwartzman reaction and of the hepatic vein thrombosis phenomenon in the rat.
Topics: Animals; Arginine; Bradykinin; Dexamethasone; Dimercaprol; Endotoxins; Esterases; Factor XII; Female | 1979 |
Inhibition of spontaneous platelet aggregation by sulfinpyrazone.
Topics: Aged; Arteriosclerosis; Diabetes Mellitus; Double-Blind Method; Humans; Hyperlipidemias; Male; Middl | 1979 |
Effects of clofibrate and sulfinpyrazone on platelet survival time in coronary artery disease.
Topics: Adult; Blood Platelets; Cell Survival; Cholesterol; Clofibrate; Coronary Disease; Humans; Hyperlipid | 1975 |
Thrombosis prevention by coagulation and platelet aggregtion inhibitors, in hyperlipemic rats.
Topics: Acenocoumarol; Adenine Nucleotides; Aniline Compounds; Animals; Anticoagulants; Blood Coagulation; B | 1970 |
[Gout in advanced age].
Topics: Age Factors; Aged; Allopurinol; Bone and Bones; Cardiovascular Diseases; Colchicine; Female; Gout; H | 1968 |